Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal
This article was originally published in PharmAsia News
Executive Summary
Takeda is the latest big pharma paying its way into Alnylam's not-so-exclusive club, with the firm having agreed to pay Alnylam $150 million upfront in exchange for worldwide, non-exclusive access to its RNA interference therapeutics platform technology in two therapeutic areas: oncology and metabolic disease
You may also be interested in...
"A Quantum Leap In Resources": Millennium CEO Dunsire In A Conversation On The Firm's First Year As Part Of Takeda (Part 1 Of 2)
On May 14, Millennium Pharmaceuticals marked its one-year anniversary as the Takeda Oncology company.
"A Quantum Leap In Resources": Millennium CEO Dunsire In A Conversation On The Firm's First Year As Part Of Takeda (Part 1 Of 2)
On May 14, Millennium Pharmaceuticals marked its one-year anniversary as the Takeda Oncology company.
RNAi Giant Alnylam Says Alliances with Japanese Pharmas Well Underway
Alnylam has been able to “accomplish a tremendous amount in a fairly short period of time by” partnering with Takeda and Kyowa Hakko Kirin, as well as Roche and Novartis, business development exec says.